Emron Managed Care News 8-7-15

New cocktails to test limits of cancer drug pricing

New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies.



ACOs Appear Unable to Incentivize Physicians to Limit Costs

Practices in affordable care organizations (ACOs) provide a slightly higher compensation for quality when compared with practices at large. Both ACO and non-ACO practices are similar, however, in regard to compensation based on productivity and salary. This suggests that the incentives for ACOs may not be strong enough to encourage practices to change physician compensation policies.



Urine Test Might Find Pancreatic Cancer Early, Study Suggests

Scientists report that they have developed a urine test that may detect pancreatic cancer at an early stage.



Half Of Nation’s Hospitals Fail Again To Escape Medicare’s Readmission Penalties

Once again, the majority of the nation’s hospitals are being penalized by Medicare for having patients frequently return within a month of discharge — this time losing a combined $420 million, government records show.



Health Law Reduces Out-Of-Pocket Expenses, But Medical Costs Can Still Be Overwhelming

One of the key aims of the health law was to protect consumers from ruinous medical debt, but some people still find it difficult to pay their health bills. Also, another health law provision created an organization to figure out which medical treatments work best to help consumers and the government save money on care.



Pharma sales predicted to top $1.3 trillion by 2018

Global pharma sales are predicted to grow to $1.3 trillion by 2018, according to a new report. Worldwide sales passed the $1 trillion mark for the first time in 2014, and the 2015 CMR Pharmaceutical R&D Factbook from Thomson Reuters predicts that this increase will continue coupled with a rise in R&D productivity.



Study finds oral contraceptives offer protection against endometrial cancer over long term

Results from a meta-analysis published in The Lancet Oncology indicate that use of oral contraceptives, even for just a few years, confers significant long-term protection against endometrial cancer. Study leader Valerie Beral said “the strong protective effect…which persists for decades after stopping the pill, means that women who use it when they are in their 20s or even younger continue to benefit into their 50s and older, when cancer becomes more common.”



ER Wait Times, Penalties, Noise Levels: Now Yelp Pairs Data On Providers With User Reviews

ProPublica teams up with Yelp to help consumers make informed health care choices by adding objective government information and ratings on hospitals, nursing homes and dialysis clinics to the website’s existing, more subjective, user-driven reviews.



Pfizer, Bristol revive cancer drugs that rev up immune system

Some of the most heralded new cancer drugs fight the disease by removing brakes on the immune system. Now a few leading drugmakers are paying attention to a second, opposing force: medicines that accelerate the immune system’s attack.